- Conditions
- Glioblastoma Multiforme, Astrocytoma, Grade III
- Interventions
- ADV/HSV-tk (gene therapy)
- Drug
- Lead sponsor
- David Baskin MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 363
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more
- Conditions
- Glioblastoma or Gliosarcoma
- Interventions
- Single intratumoral injection of DNX-2401, Interferon-gamma
- Drug
- Lead sponsor
- DNAtrix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Prostate Cancer
- Interventions
- ChAdOx1-PCAQ, MVA-PCAQ
- Biological
- Lead sponsor
- Barinthus Biotherapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- St Louis, Missouri • New York, New York • Philadelphia, Pennsylvania + 3 more
- Conditions
- Norovirus Infections
- Interventions
- VXA-GI.1.NN, Placebo Tablet
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 55 Years to 80 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 3
- States / cities
- Cypress, California • New Orleans, Louisiana • Austin, Texas
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Prednisone, LDE225
- Drug
- Lead sponsor
- Martin Gutierrez
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- recombinant interferon gamma
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Melanoma
- Interventions
- INXN-2001, INXN-1001
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more
- Conditions
- Brain Cancer, Central Nervous System Diseases
- Interventions
- DNX-2401, Tumor Removal
- Drug · Procedure
- Lead sponsor
- DNAtrix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Tivozanib, Enzalutamide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Norovirus Infection
- Interventions
- VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets
- Biological
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Adenovirus Infection
- Interventions
- Brincidofovir
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Months and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more
- Conditions
- Influenza
- Interventions
- VXA-A1.1, Fluzone®, Placebo Tablets, Saline Solution for Placebo IM Injection
- Biological · Other
- Lead sponsor
- Vaxart
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Costa Mesa, California
- Conditions
- Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
- Interventions
- Ad-P53, Xeloda, Keytruda, Opdivo
- Drug
- Lead sponsor
- MultiVir, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
- Interventions
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Biological · Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- San Francisco, California • Chicago, Illinois • Boston, Massachusetts
- Conditions
- Lung Cancer
- Interventions
- Ad5CMV-p53 gene, radiation therapy
- Biological · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Malignant Glioma, Glioblastoma Multiforme
- Interventions
- Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
- Biological
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Angina Pectoris
- Interventions
- Ad5FGF-4, Placebo
- Genetic
- Lead sponsor
- Cardium Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
- Conditions
- Viral Infections After HSCT
- Interventions
- VSTs
- Biological
- Lead sponsor
- Catherine Bollard
- Other
- Eligibility
- 4 Weeks to 45 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Lymphoma, B-Cell
- Interventions
- Adenovirus Interferon gamma
- Genetic
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 3
- States / cities
- Stanford, California • Chicago, Illinois • Houston, Texas
- Conditions
- Ebola Disease, Marburg Disease
- Interventions
- Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Autologous Dendritic Cell-Adenovirus CCL21 Vaccine, Pembrolizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Glioblastoma, Anaplastic Astrocytoma
- Interventions
- ADV/HSV-tk (gene therapy)
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pleural Mesothelioma, Metastatic Pleural Effusions
- Interventions
- Adenoviral-mediated Interferon-beta, SCH 721015
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania